Table 2 Baseline characteristics
All | Diagnostic screening | Care as usual | |
|---|---|---|---|
(n = 841) | (n = 395) | (n = 446) | |
Mean age in years ± sd | 74.6 ± 6.3 | 75.4 ± 6.2 | 73.8 ± 6.3 |
Male sex, n (%) | 418 (49.7%) | 176 (44.6%) | 242 (54.3%) |
Complaints | |||
MRC Dyspnoea score, median (IQR) | 2 (2–3) | 2 (2–3) | 2 (2–3) |
Reduced exercise tolerance questionnaire score, median (IQR) | 2 (1–3) | 2 (0–3) | 2 (1–3) |
Cardiovascular co-morbidities | |||
Ischemic heart disease, n (%) | 259 (30.8%) | 127 (32.2%) | 132 (29.6%) |
Heart failure, n (%) | 42 (5.0%) | 22 (5.6%) | 20 (4.5%) |
Valvular disorders, n (%) | 59 (7.0%) | 24 (6.1%) | 35 (7.8%) |
Cardiac rhythm disorders, n (%) | 116 (13.8%) | 55 (13.9%) | 61 (13.7%) |
Hypertension, n (%) | 591 (70.3%) | 292 (73.9%) | 299 (67.0%) |
Hypercholesterolemia, n (%) | 234 (27.8%) | 94 (23.8%) | 140 (31.4%) |
Diabetes Mellitus, n (%) | 262 (31.2%) | 130 (32.9%) | 132 (29.6%) |
CVA or TIA, n (%) | 99 (11.8%) | 44 (11.1%) | 55 (12.3%) |
Non-cardiovascular co-morbidities | |||
Visual impairment, n (%) | 207 (24.6%) | 98 (24.8%) | 109 (24.4%) |
Hearing impairment, n (%) | 93 (11.1%) | 43 (10.9%) | 50 (11.2%) |
COPD, n (%) | 134 (15.9%) | 68 (17.2%) | 66 (14.8%) |
Asthma, n (%) | 78 (9.3%) | 36 (9.1%) | 42 (9.4%) |
Mood disorders, n (%) | 27 (3.2%) | 11 (2.8%) | 16 (3.6%) |
Urinary tract problems, n (%) | 90 (10.7%) | 35 (8.9%) | 55 (12.3%) |
Osteoporosis, n (%) | 58 (6.9%) | 25 (6.3%) | 33 (7.4%) |
Malignancies, n (%) | 51 (6.1%) | 18 (4.6%) | 33 (7.4%) |
Anaemia, n (%) | 14 (1.7%) | 9 (2.3%) | 5 (1.1%) |
Renal insufficiency, n (%) | 47 (5.6%) | 12 (3.0%) | 35 (7.8%) |
Thyroid dysfunction, n (%) | 63 (7.5%) | 28 (7.1%) | 35 (7.8%) |
Osteoarthritis, n (%) | 212 (25.2%) | 126 (31.9%) | 86 (19.3%) |
Co-morbidities (number), median (IQR) | 3 (3–4) | 4 (3–4) | 3 (3–5) |
Drugs | |||
Diuretics, n (%) | 346 (41.1%) | 169 (42.8%) | 177 (39.7%) |
ACE-i/ARBs, n (%) | 478 (56.8%) | 220 (55.7%) | 258 (57.8%) |
ß-blockers, n (%) | 397 (47.2%) | 185 (46.8%) | 212 (47.5%) |
Digitalis, n (%) | 20 (2.4%) | 12 (3.0%) | 8 (1.8%) |
Oral anticoagulants, n (%) | 117 (13.9%) | 49 (12.4%) | 68 (15.2%) |
Platelet antagonists, n (%) | 402 (47.8%) | 192 (48.6%) | 210 (47.1%) |
Treatment for hypercholesterolemia | 488 (58.0%) | 209 (52.9%) | 279 (62.6%) |
Anti-diabetic drugs, n (%) | 223 (26.5%) | 109 (27.6) | 114 (25.6%) |
Treatment for COPD or Asthma, n (%) | 204 (24.3%) | 91 (23.0%) | 113 (25.3%) |
Drugs (number), median (IQR) | 6 (4–7) | 5 (4–7) | 6 (4–7) |